Zealand’s Dasiglucagon Down But Not Out In CHI?
Zealand has been hit by an unexpected Phase III failure for its glucagon analog product dasiglucagon in congenital hyperinsulinism, but all may not be lost for the indication.
You may also be interested in...
French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.
Despite being third to market behind Lilly’s Baqsimi and Xeris’s Gvoke to treat emergency episodes of hypoglycemia, Zealand is confident of a successful US launch for Zegalogue (dasiglucagon).
Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.